Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. The compound has been identified as having research potential for the treatment of dry eye disease (DED) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 125.00 | |
5 mg | 35 days | $ 490.00 | |
10 mg | 35 days | $ 875.00 |
Description | JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. The compound has been identified as having research potential for the treatment of dry eye disease (DED) [1]. |
Targets&IC50 | JAK1:15 nM, JAK2:2 nM, JAK3:18 nM, TYK2:2 nM |
Molecular Weight | 398.53 |
Formula | C19H26N8S |
CAS No. | 2891469-99-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JAK-IN-30 2891469-99-9 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK inhibitor inhibit